Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Capital Expenditures (2021 - 2025)

Prime Medicine (PRME) has disclosed Capital Expenditures for 5 consecutive years, with $290000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 95.96% year-over-year to $290000.0, compared with a TTM value of $4.5 million through Dec 2025, down 37.88%, and an annual FY2025 reading of $4.5 million, down 37.88% over the prior year.
  • Capital Expenditures was $290000.0 for Q4 2025 at Prime Medicine, down from $4.1 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $7.2 million in Q4 2024 and bottomed at -$10.3 million in Q4 2022.
  • Average Capital Expenditures over 5 years is $830764.7, with a median of $754000.0 recorded in 2021.
  • The sharpest move saw Capital Expenditures plummeted 1467.64% in 2022, then skyrocketed 11485.48% in 2024.
  • Year by year, Capital Expenditures stood at $754000.0 in 2021, then tumbled by 1467.64% to -$10.3 million in 2022, then surged by 100.6% to $62000.0 in 2023, then surged by 11485.48% to $7.2 million in 2024, then tumbled by 95.96% to $290000.0 in 2025.
  • Business Quant data shows Capital Expenditures for PRME at $290000.0 in Q4 2025, $4.1 million in Q3 2025, and -$2.3 million in Q2 2025.